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Background: In eyes with idiopathic epiretinal membrane (iERM), the intravitreal growth factor 
and cytokine levels may associate with postvitrectomy outcomes. Here, we have analyzed the 
perioperative intravitreal protein levels of potent vasoactive, proinflammatory, and extracellular 
matrix-remodeling factors in iERM eyes and evaluated the postvitrectomy outcomes.
Methods: This was an institutional, observational study. Eyes operated on for iERM (n=26) 
were analyzed according to the use of statin medication. Vitreous samples were subjected to 
protein measurements of angiopoietin-1 and -2, erythropoietin, transforming growth factor-β1, 
and vascular endothelial growth factor by enzyme-linked immunosorbent assay, and of matrix 
metalloproteinase-2 and -9 by gelatin zymography. One-month visual outcomes and 1-year 
revitrectomy rates were recorded.
Results: In iERM eyes of patients taking statins, intravitreal levels of erythropoietin 
(mean ± standard deviation, 10.8±4.9 vs 82.9±119.5 mIU/mg, P=0.003), transforming growth 
factor-β1 (2.3±4.7 vs 15.8±16.3 pg/mg, P=0.035), and vascular endothelial growth factor 
(5.5±9.9 vs 236.6±491.6 pg/mg, P=0.006) were lower than in nonstatin-treated patients. At 
1-month, visual gain did not significantly differ between iERM eyes of patients with statins 
and those without (improvement 0.27±0.20 vs 0.16±0.38 logarithm of the minimum angle of 
resolution units, P=0.118).
Conclusion: Systemic statin therapy might have a favorable effect on intravitreal factors 
involved in vascular permeability, inflammation, and fibroproliferation in aging human 
iERM eyes.
Keywords: epiretinal membrane, erythropoietin, HMG-CoA reductase inhibitors, transforming 
growth factor-beta, vascular endothelial growth factor, vitrectomy
Introduction
Despite advances in vitreoretinal microsurgery techniques over the years, epiretinal 
gliosis, such as idiopathic epiretinal membrane (iERM, also referred to as macular 
pucker), is a potentially sight-threatening vitreoretinal disorder, with aging being 
the principal nonmodifiable risk factor.1,2 Epidemiological studies have reported a 
prevalence of 1.02%–28.9% among different ethnic groups for iERM.3,4 Epiretinal 
gliosis on the macular surface ultimately leads to the formation of contractile tractional 
fibrocellular membranes, the development of severe retinal surface wrinkling, macular 
vascular distortion, and the breakdown of the blood–retinal barrier at the retinal 
pigment epithelial level. Limited understanding of the pathophysiology behind this 
vision-threatening vitreoretinal interface disease is hindering the development of 
nonsurgical treatment modalities.
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iERM involves inflammation, immune response, for 
example, classical and alternative pathway of complement 
activation, proteolysis, and cytoskeleton remodeling.5–7 
Histologically, epiretinal membrane (ERM) is composed of 
multiple retinal and extraretinal cell types and extracellular 
matrix (ECM) proteins. Most internal limiting membrane 
(ILM) specimens removed from iERMs contain activated 
cells of glial origin (Müller cells, astrocytes, and microglia), 
hyalocytes, macrophages, fibroblasts, myofibroblasts, and 
retinal pigment epithelial cells, as well as ECM components, 
including newly formed collagens.8,9 Activated astro- and 
microglial cells have been also implicated as the key 
cell types involved in central nervous system (CNS) scar 
formation, and neuroinflammation and degeneration in the 
human retina.10–12
Fibrosis in the CNS and the vitreoretinal interface, 
an abnormal wound-healing process, is often related to 
ischemia (eg, vasoconstriction predisposed by smoking) and 
neuroinflammation. This involves upregulation of proin-
flammatory and profibrotic cytokines, adhesion molecules, 
and growth factors. Matrix metalloproteinases (MMPs), a 
group of zinc- and calcium-dependent proteinases, degrade 
components of the ECM, with MMP-2 and -9 being espe-
cially associated with the development of postoperative 
proliferative vitreoretinopathy (PVR).13 Transforming 
growth factor (TGF)-β, a multifunctional cytokine, is 
implicated in both barrier breakdown-induced perme-
ability and fibroproliferation-induced contraction of PVR 
membranes.14,15 Moreover, vascular endothelial growth 
factor (VEGF) is linked to both vascular and avascular 
PVR membranes, and anti-VEGF therapies have shown a 
prophylactic effect against postoperative PVR formation.16,17 
Angiopoietins (ANGPTs), potent regulators of endothelial 
cell–cell and cell–ECM interactions, were recently suggested 
as potential therapeutic targets in both neurotrauma and 
ischemia–reperfusion studies.18,19
Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase inhibitors, were shown to reduce neuroinflammation 
and astrocyte activation in CNS injuries and enhance ganglion 
cell survival of ischemic rat retinas.20–22 In eyes subjected to 
surgery for fibroproliferative vitreoretinal disease, microvascu-
lar- and neuroprotective actions of statins23–25 might modulate 
integrity of the blood–retinal barrier, retinal wound healing, 
inflammation-related PVR, and photoreceptor survival.26,27
In the present study, we investigated the intravitreal 
levels of vasoactive, proinflammatory, and fibrotic factors; 
the visual outcomes; and the probability of reoperations 
in a group of vitrectomized iERM patients on statin 
medication compared with patients without preoperative 
statin medication.
Materials and methods
study design
Patients were admitted for primary vitrectomy for manage-
ment of iERM in the Unit of Vitreoretinal Surgery, Helsinki 
University Central Hospital, Helsinki, Finland. The study 
was conducted according to the tenets of the Declaration of 
Helsinki and was approved by the Institutional Review Board 
of Helsinki University Central Hospital. Signed informed 
consent was obtained from each participant before sampling. 
Confidentiality of the patient records was maintained 
when the clinical data were entered into a computer-based 
standardized data entry for analysis.
Patients and controls
In this study, a total of 26 eyes of 25 patients who underwent 
primary vitrectomy for iERM between 2006 and 2008 were 
studied. Diagnosis of iERM was performed using optical 
coherence tomography. Data were further analyzed according 
to the use or nonuse of lipid-lowering statin therapy. Of the 
26 cases, 12 were on statin treatment (nine on lipophilic simvas-
tatin and three on lipophilic atorvastatin), and 14 were without 
any statins. Exclusion criteria were other retinal comorbidities 
such as diabetic retinopathy, inflammatory or retinal vascular 
disorder, or trauma. The clinical characteristics and concomi-
tant interfering medication of the study patients are presented 
in Tables 1 and 2. Time of exposure to statin therapy was not 
documented in our study. The decision for statin therapy was 
taken by the general practitioner or internal medicine doctor.
surgery
Undiluted vitreous samples (up to 1,000 µL) were collected 
at the start of the standard three-port pars plana vitrectomy 
(20 or 23 Gauge, Accurus, Alcon Instruments, Inc, Fort 
Worth, TX, USA) without an infusion of artificial fluid. The 
samples were collected by manual aspiration into a syringe 
via the vitrectomy with the cutting function activated. Sam-
ples were transferred into sterile 1.5 mL Eppendorf tubes and 
immediately frozen at −70°C until laboratory analysis.
The surgical technique consisted of a standard three-
port pars plana vitrectomy. If the vitreous was attached 
to the posterior retina, posterior vitreous detachment was 
induced by suction with the vitrectomy probe over the 
optic disc. To visualize and identify the posterior hyaloid, 
ERMs and the ILM, intravitreal vital dyes were used 
(chromovitrectomy). Diluted indocyanine green and/or 
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Table 1 Baseline characteristics
Patient and ocular variables Nonstatin (n=14) Statin (n=12) P-value
age (years) 69.5±7.0 69.9±4.6 0.667
Male:female, n (%) 7:7 (50:50) 3:9 (25:75) 0.191
BMi (kg/m2) 29.9±12.0 27.5±3.9 0.979
asa class (1–4) 2.5±0.5 2.7±0.5 0.084
smoking, n (%) 9 (64) 7 (58) 0.756
systolic BP (mmhg) 159.2±28.9 149.2±21.8 0.437
Diastolic BP (mmhg) 83.1±11.5 84.5±11.4 0.574
intraocular pressure (mmhg) 15.0±2.9 14.5±3.4 0.769
Pseudophakic (iOl), n (%) 4 (29) 6 (50) 0.263
Notes: Data presented as mean ± sD or absolute number and proportion. For two-group comparisons, qualitative data were analyzed by two-factor χ2 test and continuous 
variables by nonparametric Mann–Whitney U-test.
Abbreviations: asa, american society of anesthesiologists; BMi, body mass index; BP, blood pressure; iOl, intraocular lens; sD, standard deviation.
Table 2 Concomitant medication of the study patients
Medication Nonstatin (n=14) Statin (n=12) P-value
hypercholesterolemia
Fibrate 1 0 0.345
statin (simvastatin:atorvastatin) 0 12 (9:3)
Diabetes
Oral only:insulin only:combination 3 (1:0:2) 2 (2:0:0) 0.759
hypertension
aCe:aT2 3 4 0.495
β-Blocker 5 6 0.462
Calcium channel blocker  
(vascular:cardioselective) 
3 2 0.759
Diuretic 2 3 0.490
Circulation
anticoagulation 0 1 0.271
antithrombotic 6 6 0.716
inotropic 1 0 0.345
nitrate 2 2 0.867
Central nervous system
antidepressive 0 3 0.047
Benzodiazepine 0 1 0.271
Dementia 1 0 0.345
nonbenzodiazepine hypnotic 0 1 0.271
gastrointestinal tract
Proton pump inhibitor 2 2 0.867
Other hormones and vitamins
BPh 1 1 0.910
hormonal substitution 3 2 0.759
Thyroxin 1 2 0.449
Vitamins and micronutrients* 2 3 0.490
immunomodulation
antihistamines 3 1 0.356
glucocorticoid 1 0 0.345
glucocorticoid inhalated 2 5 0.117
nsaiDs 0 1 0.271
infection
antibiotic 1 0 0.345
Topical medication
allergy 1 0 0.345
glaucoma 0 1 0.271
Notes: Data presented as n-value of concomitant preoperative medication of 14 eyes of 14 nonstatin and 12 eyes of eleven statin-treated patients. For two-group 
comparisons, qualitative data were analyzed by two-factor χ2 test. *Vitamins and micronutrients counted by prescription. P0.05 shows a statistically significant result 
between the groups.
Abbreviations: aCe, angiotensin converting enzyme inhibitor; aT2, angiotensin ii receptor antagonist; BPh, benign prostatic hyperplasia; nsaiDs, nonsteroidal 
anti-inflammatory drugs.
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MembraneBlue-Dual® (D.O.R.C., Zuidland, the Nether-
lands) dye-assisted ERM ± ILM peeling was performed. 
Air–fluid exchange and flushing of the vitreous cavity 
with SF
6
 (sulfur hexafluoride) was performed in six eyes 
(23.1%), C
2
F
6
 (hexafluoroethane) in ten eyes (38.5%), and 
C
3
F
8
 (octafluoropropane) in one eye (3.8%). Nine (34.6%) 
eyes were filled with balanced salt solution.
Determination of biomarkers
Frozen vitreous humor samples were thawed and clarified 
by centrifugation at 13,000 rpm at room temperature 
for 5 minutes. A reference serum sample was used to 
calculate intra- and inter-assay variation. Standard curves 
were constructed by plotting the concentration and mean 
absorbance and the plates were analyzed using a Victor2 
multilabel counter microplate reader (Wallac, Turku, 
Finland) at a wavelength of 450 nm. To calculate the con-
centration, the standards were fitted with a second-order 
polynomial equation.
For ANGPT-1 and -2 measurements in vitreous samples, 
we used solid-phase enzyme-linked immunosorbent assay 
(ELISA) kits (DANG10 and DANG20, R&D Systems, 
Minneapolis, MN, USA). Total TGF-β1 and VEGF levels 
in the vitreous were measured using Quantikine ELISA kits 
(DB100B and DVE00, respectively, R&D Systems). Latent 
forms of TGF-β1 were acid-activated before the assay 
according to the manufacturer’s instructions. Erythropoietin 
(EPO) levels in the vitreous were determined by a Quantikine 
human EPO IVD ELISA (DEP00, R&D Systems).
Gelatin zymography was performed to evaluate total 
MMP-2 and -9 zymogens in the vitreous samples. To analyze 
the gelatinolytic proteins, aliquots of vitreous samples were 
subjected to gelatin zymography.28 Samples were dissolved in 
nonreducing Laemmli sample buffer and separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis using 
10% polyacrylamide gels containing 1 mg/mL of gelatin. 
After electrophoresis, the gels were washed twice with 50 
mM Tris–HCl, pH 7.6, containing 5 mM CaCl
2
, 1 µM ZnCl
2
, 
2.5% Triton X-100 (v/v) for 15 minutes to remove sodium 
dodecyl sulfate, followed by a brief rinse in washing buffer 
without Triton X-100. The gels were then incubated at 37°C 
for 12–24 hours in 50 mM Tris–HCl buffer containing 5 mM 
CaCl
2
, 1 µM ZnCl
2
, 1% Triton X-100, 0.02% NaN
3
, pH 7.6. 
The gels were stained with Coomassie brilliant blue R250 fol-
lowed by destaining with 10% acetic acid and 5% methanol. 
The zymogen gels were later scanned by an image scanner, 
and the areas of clear bands corresponding to MMP-2 and -9 
activity were calculated using ImageJ software (v1.42q, NIH, 
Bethesda, MD, USA) on nonaltered original Tagged Image 
File Format files in the 8-bit dynamic range of signal intensi-
ties. The values are reported in arbitrary units (AU/mL).
Total protein measurement
Vitreous total protein concentrations (mg/mL) were measured 
to compare the undiluted vitreous catch between study groups 
using a bicinchonic acid protein assay kit (Pierce, Rockford, 
IL, USA) according to manufacturer’s instructions. The 
intravitreal concentrations (ANGPT-1 and -2, VEGF, TGF-β1 
[pg/mL]; EPO [mIU/mL]; or MMP-2 and -9 [AU/mL]) in eyes 
with iERM are given in relation to total protein concentration 
(mg/mL) in the vitreous sample.
Visual acuity testing
Best-corrected visual acuity (BCVA) was measured in a 
single sitting under standardized low light conditions on a 
standard Snellen chart at an observation distance of 5 m. 
When the largest optotype could not be correctly recognized, 
the classification was very low VA on a semiquantitative 
scale such as counting fingers, hand motion, light perception, 
or no light perception. For statistical purposes, the Snellen 
values were transformed to the equivalent logarithm of the 
minimum angle of resolution (LogMAR) units. Very low 
VA measurements were converted as follows: counting 
fingers 1.9, hand motion 2.3, light perception 2.7, and no 
light perception 3.0 LogMAR.29
statistical analyses
All data are presented as mean ± standard deviation, except 
for the absolute number and proportion for the nominal scale, 
and data were analyzed with SPSS 15.0 (SPSS Inc, Chicago, 
IL, USA). For two-group comparisons, qualitative data were 
analyzed using the two-factor χ2 test and continuous variables 
with the nonparametric Mann–Whitney U-test. Associations 
between variables were analyzed by Pearson’s correlation. 
The need of revitrectomy was analyzed using the log-rank test. 
Death and the end of follow-up at 1 year were used as censor-
ing events. P0.05 was considered statistically significant.
Results
Baseline characteristics of the patients 
and vitrectomized eyes
The study groups were age- and sex-matched (Table 1). 
All the subjects were of Caucasian origin. Interestingly, the 
majority of patients (58%–64%) were smokers in both study 
groups (Table 1). The concomitant medication of the patients 
was similar between the groups, except for the fact that 
statin-treated patients had a higher probability of concomitant 
antidepressive medication (P=0.047, Table 2).
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intravitreal protein levels
The intravitreal protein levels of EPO (P=0.003, Table 3), 
TGF-β1 (P=0.035, Table 3), and VEGF (P=0.006, Table 3) 
were significantly lower in the statin-treated compared 
to nonstatin-treated patients with iERM. No difference 
emerged in the intravitreal ANGPT-1 and -2, or MMP-2 
and -9 (Table 3), or the plasma ANGPT-1 and -2 (Table S1) 
protein levels between the study groups. Intravitreal EPO 
levels correlated significantly with those of intravitreal VEGF 
(r=0.892, P<0.001) and TGF-β1 (r=0.695, P=0.001) levels 
(data not shown).
Postoperative outcomes
Preoperatively, the mean BCVA of iERM eyes did not 
differ between statin- and nonstatin-treated study patients 
(Table 4). Both the 1-month mean postoperative BCVA 
(P=0.053, Table 4) and BCVA gain (P=0.118, Table 4) 
did not significantly differ between the statin- compared to 
nonstatin-treated patients.
The number of eyes requiring revitrectomy during a 
12-month follow-up was one of 12 in the statin group (due 
to rhegmatogenous retinal detachment [RRD]) and four of 14 
in the nonstatin group (one due to RRD, one due to inferior 
PVR and RRD, and two due to recurrent ERM formation) 
(P=0.219, Table 4). All secondary RRD cases occurred within 
3–5 weeks of postprimary vitrectomy; they were reoperated 
and the retina was successfully reattached with gas or silicone 
oil. No endophthalmitis or prolonged hypotony was noted in 
the study eyes during the 12-month follow-up period.
Discussion
The vitreoretinal interface disease iERM is a common 
age-associated sight-threatening disorder worldwide, with 
aging and the development of anomalous posterior vitreous 
detachment being the most important known risk factors.2 
However, the underlying mechanisms of iERM formation 
remain unclear. Numerous studies have reported intravit-
real biochemical factors associated with secondary puckers 
related to various posterior segment inflammatory diseases, 
venous occlusive diseases, diabetic retinopathy, RRD, 
retinopathy of prematurity, and vitreomacular traction syn-
dromes in age-related macular degeneration with choroidal 
neovascularization or diabetic macular edema. However, 
reports of intravitreal biochemical factors in iERM formation 
are rather scarce.8 Thus, our finding that several intravitreal 
vasoactive, proinflammatory, and profibrotic biomarkers in 
iERM eyes seem to be regulated by statin could be of great 
clinical importance regarding future therapeutic approach.
The aging process in CNS is known to be associated 
with degenerative changes such as presence of oxidative, 
proteotoxic, and metabolic stresses.30 Glial cell responses 
seem to be similar in the brain and neural retina.12 Comor-
bidities, such as long-term smoking, systemic hypertension, 
hyperlipidemia, obesity, or ischemia with an inflammatory 
component, could also play a role in the development of these 
age-related eye diseases. Indeed, majority of our patients 
were current smokers. Lifetime exposure to smoking could 
be related to increased oxidative stress and free radical 
generation, both of which are known to serve as triggers for 
parainflammation, vascular dysfunction, and fibroprolifera-
tion at the CNS and retinal level.31,32 Depending on the genetic 
background, smoking may affect the reparative potential of 
eye fibroblasts and promote the activation of proinflamma-
tory pathways.33 Modern brain imaging techniques, such as 
advanced magnetic resonance imaging or positron emission 
tomography, could be useful in correlating the results with 
fibrosis formation in iERM eyes to assess the extent of gliosis/
fibrosis formation in the CNS.
Table 3 intravitreal protein concentrations in nonstatin- and 
statin-treated ierM patients
Nonstatin (n=14) Statin (n=12) P-value
Total protein 3.3±2.3 4.1±1.3 0.095
angPT-1 27.8±39.1 12.3±6.1 0.145
angPT-2 82.9±108.5 31.8±22.0 0.176
ePO 82.9±119.5 10.8±4.9 0.003
MMP-2 1,710.0±1,185.7 854.1±496.8 0.072
MMP-9 36.7±47.7 43.8±77.5 1.000
TgF-β1 15.8±16.3 2.3±4.7 0.035
VegF 236.6±491.6 5.5±9.9 0.006
Notes: The intravitreal concentrations (angPT-1 and -2, VegF, TgF-β1 [pg/ml]; 
ePO [miU/ml]; or MMP-2 and -9 [aU/ml]) in eyes with ierM are given in relation 
to total protein concentration (mg/ml) in the vitreous sample. Data presented as 
mean ± seM. For two-group comparisons, a nonparametric Mann–Whitney U-test 
was used. P0.05 shows a statistically significant result between the groups.
Abbreviations: angPT, angiopoietin; ePO, erythropoietin; ierM, idiopathic 
epiretinal membrane; MMP, matrix metalloproteinase; seM, standard error of mean; 
TgF-β1, transforming growth factor-β1; VegF, vascular endothelial growth factor.
Table 4 One-month mean BCVa and 12-month revitrectomy of 
the study eyes
Nonstatin (n=14) Statin (n=12) P-value
BCVa (pre) 0.76±0.43 0.63±0.17 0.527
BCVa (1-month) 0.61±0.32 0.37±0.16 0.053
BCVa gain 0.16±0.38 0.27±0.20 0.118
revitrectomy  
(12-month)
4 1 0.219
Notes: Data presented as mean ± sD or as number of eyes of observed events in 
the two groups. For two-group comparisons, continuous variables were analyzed 
by nonparametric Mann–Whitney U-test and hazard of revitrectomy was analyzed 
using log-rank test. BCVa are given as logMar units.
Abbreviations: BCVa, best-corrected visual acuity; logMar, logarithm of the 
minimum angle of resolution; sD, standard deviation.
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Recent advances in proteomics, for example, have 
revealed that TGF-β1 is involved in iERM formation.5 
TGF-β1 is known to be present at low levels in the adult CNS. 
Microglia, infiltrating monocytes/macrophages, platelets, 
and reactive astrocytes are the major sources of increased 
TGF-β1 during the early degenerative, remodeling, and heal-
ing phases in CNS disorders, such as ischemia and trauma.34,35 
In the CNS, TGF-β1 can also act as a secondary mediator 
of injury and promote astrocyte activation together with 
interleukins, fibrinogen, nuclear factor kappa beta and signal 
transducer and activator of transcription 3 and stimulate them 
to transdifferentiate into contractile myofibroblasts.36,37 In 
our study, the fact that TGF-β1 levels in the eyes of patients 
with statin therapy were decreased compared with the levels 
in the nonstatin group could be due to differences in tissue 
remodeling mechanisms, perhaps reduced wound healing 
activity and epithelial-to-mesenchymal transition in eyes 
operated for iERM.14,38
At best, surgical intervention is the choice of treatment 
only for a proportion of iERM cases. Furthermore, both exist-
ing intraocular fibrosis may cause irreversible tissue injury 
per se in the sensitive neuroretina and surgical removal of 
ERM may damage the nerve fiber layer, preventing the recov-
ery of visual acuity even after a successful surgical procedure. 
Pharmacological interventions targeting CNS fibrosis would 
be of great importance. Statin use may modulate expression 
of proteins and cytokines associated with wound healing 
and survival.39 Furthermore, the role of angiogenic and 
antiangiogenic factors in iERM (eg, soluble VEGF receptor 
[s-VEGFR-1]) remains a topic for further research.40 In the 
future, the use of proteomics and genetics might enable bet-
ter understanding of the pathophysiology of these complex 
age-related vitreoretinal interface disorders and improve 
nonsurgical treatment modalities for them.41
The major strength of our study was its measurement of 
several intravitreal vasoactive, proinflammatory, and pro-
fibrotic biomarkers in patients admitted for primary vitrec-
tomy for iERM. However, our study has several limitations. 
First, we did not excise the membranes for immunocytochem-
ical or ultrastructural analysis, and the number of intravitreal 
specimens was limited in both groups. Second, our study 
design did not allow additional postoperative controls after 
1 month, thus the follow-up does not provide the anatomi-
cal optical coherence tomography outcome results, and the 
documentation for need of reoperations is retrospective in 
nature. Our present preliminary findings, however, suggest 
that statin treatment might have a role in anti-inflammatory 
and antifibrotic process in the aging human eye.
Conclusion
To conclude, the pathogenesis of fibrosis formation in the 
CNS and the aging eye is poorly understood, but can represent 
the end result of inflammation, apoptosis, proliferation, and 
abnormal wound healing. Currently, treatment strategies are 
limited, consisting of ophthalmic follow-up or microsurgery 
with pars plana vitrectomy with membrane peeling. Under-
standing of the regulation of fibrosis and modification of the 
fibrotic process is crucial to improve the surgical outcome 
of eyes with iERM. With the aging of the global population 
and the increasing life expectancy, the need for prevention 
and/or novel therapeutic approaches for fibrotic vitreoretinal 
interface diseases is growing.
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Supplementary material
Table S1 Plasma protein concentrations in nonstatin- and statin-treated ierM patients
Nonstatin (n=14) Statin (n=12) P-value
angPT-1 3,112.5±2,018.1 3,888.4±2,517.2 0.456
angPT-2 2,297.3±725.8 2,356.1±971.2 1.000
Notes: The plasma concentrations (angPT-1 and -2 [pg/ml]) in patients with ierM. Data presented as mean ± sD. For two group comparisons, a nonparametric Mann–
Whitney U-test was used.
Abbreviations: angPT, angiopoietin; ierM, idiopathic epiretinal membrane; sD, standard deviation.
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